Drugs & Targets FDA issues additional draft guidance on eligibility criteria for cancer drug clinical trials May 03, 2024Vol.50 No.18
Regulatory News ODAC unanimously upholds MRD as early endpoint across all settings in multiple myeloma April 26, 2024Vol.50 No.17By Jacquelyn Cobb
Conversation with The Cancer Letter Clearing the path for MRD as early endpoint in multiple myeloma April 26, 2024Vol.50 No.17By Jacquelyn Cobb
Drugs & Targets FDA approves Anktiva for non-muscle-invasive bladder cancer April 26, 2024Vol.50 No.17
Drugs & Targets FDA revises industry guidance on biologics promotion and advertising April 26, 2024Vol.50 No.17
Funding Opportunities FDA offers funding for meetings on medical policy activities April 19, 2024Vol.50 No.16
Drugs & Targets FDA approves Alecensa for ALK-positive early-stage lung cancer April 19, 2024Vol.50 No.16
Drugs & Targets FDA grants accelerated approval to Enhertu for unresectable or metastatic HER2-positive solid tumors April 12, 2024Vol.50 No.15
